An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL
Mazyar Shadman(University of Washington), Talha Munir(Leeds Teaching Hospitals NHS Trust), Jamie Hirata(Universidad San Carlos), Keri Yang(Universidad San Carlos), Constantine S. Tam(Alfred Health), Rhys Williams(Universidad San Carlos), Sheng Xu(Danone (China)), Tian Tian(Universidad San Carlos), Marcus Lefebure(Peter MacCallum Cancer Centre), Danielle M. Brander(Duke University)
Cited by 1
Related Papers
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
|The Lancet Oncology|2017|327
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
|PubMed|2020|143
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
|Clinical Cancer Research|2020|115
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
|Journal of the National Comprehensive Cancer Network|2019|94